Takeda leverages lung cancer awareness month to highlight ALK variant

Takeda building
For every insight and story shared with the hashtag #tALKpositiveNSCLC during the month, Takeda will make a donation to the Bonnie J. Addario Lung Cancer Foundation.

Takeda’s is putting the tALK in ALK-positive lung cancer with a new awareness campaign. Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer, which affects between 2% and 8% of all non-small cell lung cancer patients.

The digital and social media effort encourages patients, caregivers and healthcare providers to share positive experiences and stories.

“The concept of ‘talk positively’ has different meanings. There’s the awareness around the ALK-positive genetic mutation, and there’s also the opportunity to de-stigmatize and provide hope to the lung cancer community,” Fatima Scipione, senior director of patient advocacy for Takeda Oncology, said.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Takeda, sporting a new-look portfolio, revs for Roche battle in ALK lung cancer

For every insight and story shared with the hashtag #tALKpositiveNSCLC during the month, Takeda will make a donation to the Bonnie J. Addario Lung Cancer Foundation.

Along with the campaign, Takeda is also launching its first registry for ALK-positive patients. The ALKConnect Registry will collect information and insights from patients living with ALK-positive NSCLC who opt into the database. The patients can then participate in surveys and share experiences as well as access data and insights from other patients and find out about new research studies.

RELATED: Takeda cuts 180 Ariad workers as it grabs synergies from $5.2B buyout

Takeda won accelerated approval in the spring for Alunbrig to treat patients with ALK-positive NSCLC who have failed on or are intolerant to Pfizer's Xalkori. Takeda acquired Alunbrig through its purchase of Boston biotech Ariad, which closed early this year, but the Japanese drugmaker already faces new competition from Roche’s Alecensa which was recently approved to treat newly diagnosed patients with ALK-positive disease.

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.